In his research, Dr. Gadgeel conducts clinical trials in search of new treatment options for lung cancer, including mesothelioma. One of Dr. Gadgeel’s studies targeted new chemotherapy options for patients with peritoneal mesothelioma, or mesothelioma of the abdominal walls. His research, conducted at Karmanos and at SWOG, a highly respected cooperative group that supports clinical trials, has been supported with grants from the National Cancer Institute, Southwest Oncology Group, universities and pharmaceutical companies.
In addition to his research and work with patients, Dr. Gadgeel is a teacher, currently serving as associate professor in the Division of Hematology & Oncology at Karmanos Cancer Center/Wayne State University. He participates on several faculty committees at Karmanos, including those that set standards for quality patient care, and his work has been recognized by the Wayne State University School of Medicine Teaching Award and a Merit Award from the Society of Clinical Oncology.
Main Speciality: Oncology
Other Interests & Specialties: General oncology, hematologic oncology, drug development for lung cancer and thoracic cancers.
Certifications, Awards & Accolades: American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Certification in Medical Oncology, member of the American Society of Clinical Oncology (ASCO), member of the International Association for the Study of Lung Cancer (IASLC)
Education & Experience:
- Internship in Internal Medicine at North Shore University Hospital
- Residency in Internal Medicine at Wayne State University School of Medicine
- Fellowship in Medical Oncology at Wayne State University School of Medicine
- Medical Degree from Grant Medical College
Phase II Study of Cediranib in Patients with Malignant Pleural Mesothelioma. Journal of Thoracic Oncology. November 2011;6(11):1938-45. doi: 10.1097/JTO.0b013e318229586e
Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology. June 2016;11(6):900-9. doi: 10.1016/j.jtho.2016.02.006
Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)-Medicare investigation of treatment patterns and overall survival. Clinical Epidemiology. October 2016;8:743-750. doi: 10.2147/CLEP.S105396
Novel combinations using pemetrexed in malignant mesothelioma. Clinical Lung Cancer. 2004 April 2004;5(2):S61-6.
Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. The Journal of Clinical Oncology. July 2008;26(21):3567-72. doi: 10.1200/JCO.2007.15.2868
A finalized phase II report of pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients with peritoneal mesothelioma (PM). Journal of Clinical Oncology. June 2006;24:18S – Abstract 2050.
- Mesothelioma Doctors
- Cancer Centers
- Treatment Near You
- Experimental Treatments
- Alternative Treatments
- Clinical Trials
- Caregiver Resources
- Treatment Costs